Literature DB >> 11348743

Heparin in the treatment of burns: a review.

M J Saliba.   

Abstract

Burns are difficult to treat, wounds with complex local and systemic pathology and high mortality, that often heal slowly with scars and contractures. Glycosaminoglycans (GAGs) have been used in parenteral and topical application studies. These studies have uncovered anticoagulative, antiinflammatory and neoangiogenic properties, which may stimulate tissue repair and reepithelializing effects. The endogenous GAGs utilized in treating burns are heparin, dermatan sulfate, heparan sulfate, keratin sulfate, chondroitin-4- and chondroitin-6-sulfate, and hyaluronic acid. Heparin, the most sulfated and acidic GAG, has been used parenterally, topically, by inhalation, in pellet, and in bioengineered membranes. Heparin relieved pain, inhibited clotting and inflammation, restored blood flow, and enhanced healing. Heparin effects that improved and reduced burn care were time, dose, pH, site, source and duration related in studies. Potential adverse effects with heparin use are bleeding, thrombocytopenia and allergy. Heparin preserved lung and improved function. Heparin preserved intestinal integrity and reduced bacterial translocation. Collagen restoration was enhanced. The healed skin was smooth. Heparin reduced needs for pain medicine, topical antibiotics, resuscitation fluids, blood, water baths, debridement, surgery and grafts. Cost of treatments were reduced. Although not as yet fully substantiated, topical heparin therapy of burns may be a useful addition to the range of available treatments for burn wounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11348743     DOI: 10.1016/s0305-4179(00)00130-3

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  16 in total

1.  Low molecular weight heparin-induced pharmacological modulation of burn wound healing.

Authors:  T Ravikumar; N Shanmugasundaram; V Jayaraman; K M Ramakrishnan; M Babu
Journal:  Ann Burns Fire Disasters       Date:  2006-09-30

2.  Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs.

Authors:  Malathi Erickson; Linda M Hiebert; Anthony P Carr; Jocelyn D Stickney
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

3.  Regulation of PMA-induced MUC5AC expression by heparin in human bronchial epithelial cells.

Authors:  Qi Li; Rui Xia Lei; Xiang Dong Zhou; Victor P Kolosov; Juliy M Perelman
Journal:  Mol Cell Biochem       Date:  2011-10-05       Impact factor: 3.396

4.  The efficacy of recombinant human activated protein C (rhAPC) vs antithrombin III (at III) vs heparin, in the healing process of partial-thickness burns: a comparative study.

Authors:  O Kritikos; M Tsagarakis; D Tsoutsos; C Kittas; V Gorgoulis; A Papalois; A Giannopoulos; G Kakiopoulos; O Papadopoulos
Journal:  Ann Burns Fire Disasters       Date:  2012-06-30

Review 5.  Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review.

Authors:  Andrew C Miller; Elamin M Elamin; Anthony F Suffredini
Journal:  Crit Care Med       Date:  2014-02       Impact factor: 7.598

Review 6.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

7.  Antithrombin III Prevents Early Bacterial Translocation in Burn Injury.

Authors:  O Herek; M Yılmaz; I Kaleli; N Cevahir; N Demirkan
Journal:  Ann Burns Fire Disasters       Date:  2006-12-31

8.  Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase.

Authors:  Song Chen; Xiaojuan Zhang; Yini Sun; Ziwei Hu; Siyu Lu; Xiaochun Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 9.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

10.  Hyaluronan- and heparin-reduced silver nanoparticles with antimicrobial properties.

Authors:  Melissa M Kemp; Ashavani Kumar; Dylan Clement; Pulickel Ajayan; Shaker Mousa; Robert J Linhardt
Journal:  Nanomedicine (Lond)       Date:  2009-06       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.